293 related articles for article (PubMed ID: 28665416)
1. A gene expression signature distinguishes innate response and resistance to proteasome inhibitors in multiple myeloma.
Mitra AK; Harding T; Mukherjee UK; Jang JS; Li Y; HongZheng R; Jen J; Sonneveld P; Kumar S; Kuehl WM; Rajkumar V; Van Ness B
Blood Cancer J; 2017 Jun; 7(6):e581. PubMed ID: 28665416
[TBL] [Abstract][Full Text] [Related]
2. In vitro and ex vivo gene expression profiling reveals differential kinetic response of HSPs and UPR genes is associated with PI resistance in multiple myeloma.
Mitra AK; Kumar H; Ramakrishnan V; Chen L; Baughn L; Kumar S; Rajkumar SV; Van Ness BG
Blood Cancer J; 2020 Jul; 10(7):78. PubMed ID: 32724061
[TBL] [Abstract][Full Text] [Related]
3. The power of proteasome inhibition in multiple myeloma.
Guerrero-Garcia TA; Gandolfi S; Laubach JP; Hideshima T; Chauhan D; Mitsiades C; Anderson KC; Richardson PG
Expert Rev Proteomics; 2018 Dec; 15(12):1033-1052. PubMed ID: 30427223
[TBL] [Abstract][Full Text] [Related]
4. Safety of proteasome inhibitors for treatment of multiple myeloma.
Schlafer D; Shah KS; Panjic EH; Lonial S
Expert Opin Drug Saf; 2017 Feb; 16(2):167-183. PubMed ID: 27841029
[TBL] [Abstract][Full Text] [Related]
5. Gene Networks Constructed Through Simulated Treatment Learning can Predict Proteasome Inhibitor Benefit in Multiple Myeloma.
Ubels J; Sonneveld P; van Vliet MH; de Ridder J
Clin Cancer Res; 2020 Nov; 26(22):5952-5961. PubMed ID: 32913136
[TBL] [Abstract][Full Text] [Related]
6. Proteasome inhibitors - molecular basis and current perspectives in multiple myeloma.
Kubiczkova L; Pour L; Sedlarikova L; Hajek R; Sevcikova S
J Cell Mol Med; 2014 Jun; 18(6):947-61. PubMed ID: 24712303
[TBL] [Abstract][Full Text] [Related]
7. [Role of novel proteasome inhibitors in the treatment of relapsed/refractory multiple myeloma].
Ri M
Rinsho Ketsueki; 2018; 59(10):2162-2168. PubMed ID: 30305522
[TBL] [Abstract][Full Text] [Related]
8. Spotlight on ixazomib: potential in the treatment of multiple myeloma.
Muz B; Ghazarian RN; Ou M; Luderer MJ; Kusdono HD; Azab AK
Drug Des Devel Ther; 2016; 10():217-26. PubMed ID: 26811670
[TBL] [Abstract][Full Text] [Related]
9. Old and new generation proteasome inhibitors in multiple myeloma.
Montefusco V; Mussetti A; Salas MQ; Martinelli G; Cerchione C
Panminerva Med; 2020 Dec; 62(4):193-206. PubMed ID: 32957744
[TBL] [Abstract][Full Text] [Related]
10. Optimizing Immunomodulatory Drug With Proteasome Inhibitor Combinations in Newly Diagnosed Multiple Myeloma.
Ntanasis-Stathopoulos I; Terpos E; Dimopoulos MA
Cancer J; 2019; 25(1):2-10. PubMed ID: 30694854
[TBL] [Abstract][Full Text] [Related]
11. Research progress in proteasome inhibitor resistance to multiple myeloma.
Wu J; Liu J
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2021 Aug; 46(8):900-908. PubMed ID: 34565737
[TBL] [Abstract][Full Text] [Related]
12. MAFb protein confers intrinsic resistance to proteasome inhibitors in multiple myeloma.
Qiang YW; Ye S; Huang Y; Chen Y; Van Rhee F; Epstein J; Walker BA; Morgan GJ; Davies FE
BMC Cancer; 2018 Jul; 18(1):724. PubMed ID: 29980194
[TBL] [Abstract][Full Text] [Related]
13. The effects of proteasome inhibitors on bone remodeling in multiple myeloma.
Zangari M; Suva LJ
Bone; 2016 May; 86():131-8. PubMed ID: 26947893
[TBL] [Abstract][Full Text] [Related]
14. Second Generation Proteasome Inhibitors in Multiple Myeloma.
Gozzetti A; Papini G; Candi V; Brambilla CZ; Sirianni S; Bocchia M
Anticancer Agents Med Chem; 2017; 17(7):920-926. PubMed ID: 27592543
[TBL] [Abstract][Full Text] [Related]
15. Role of Proteasome Inhibitors in Relapsed and/or Refractory Multiple Myeloma.
Leleu X; Martin TG; Einsele H; Lyons RM; Durie BGM; Iskander KS; Ailawadhi S
Clin Lymphoma Myeloma Leuk; 2019 Jan; 19(1):9-22. PubMed ID: 30287200
[TBL] [Abstract][Full Text] [Related]
16. New orally active proteasome inhibitors in multiple myeloma.
Allegra A; Alonci A; Gerace D; Russo S; Innao V; Calabrò L; Musolino C
Leuk Res; 2014 Jan; 38(1):1-9. PubMed ID: 24239172
[TBL] [Abstract][Full Text] [Related]
17. Proteasome inhibitors for the treatment of multiple myeloma.
Scalzulli E; Grammatico S; Vozella F; Petrucci MT
Expert Opin Pharmacother; 2018 Mar; 19(4):375-386. PubMed ID: 29478351
[TBL] [Abstract][Full Text] [Related]
18. Ixazomib for the treatment of multiple myeloma.
Gentile M; Offidani M; Vigna E; Corvatta L; Recchia AG; Morabito L; Morabito F; Gentili S
Expert Opin Investig Drugs; 2015; 24(9):1287-98. PubMed ID: 26138345
[TBL] [Abstract][Full Text] [Related]
19. [Proteasome inhibitors in first-line treatment of transplant-ineligible multiple myeloma patients].
Kuroda J; Shimura Y
Rinsho Ketsueki; 2017; 58(8):999-1005. PubMed ID: 28883286
[TBL] [Abstract][Full Text] [Related]
20. TOP2A expression predicts responsiveness to carfilzomib in myeloma and informs novel combinatorial strategies for enhanced proteasome inhibitor cell killing.
Reale A; Khong T; Mithraprabhu S; Savvidou I; Hocking J; Bergin K; Ramachandran M; Chen M; Dammacco F; Ria R; Silvestris F; Vacca A; Reynolds J; Spencer A
Leuk Lymphoma; 2021 Feb; 62(2):337-347. PubMed ID: 33131357
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]